Nintedanib and pirfenidone inhibit collagen synthesis and maturation at several regulatory levels

Larissa Knüppel (Munich, Germany), Larissa Knüppel, Yoshihiro Ishikawa, Michaela Aichler, Katharina Heinzelmann, Rudolf Hatz, Jürgen Behr, Axel Walch, Hans Peter Bächinger, Oliver Eickelberg, Claudia A. Staab-Weijnitz

Source: International Congress 2016 – ILD pathogenesis
Session: ILD pathogenesis
Session type: Poster Discussion
Number: 3093
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Larissa Knüppel (Munich, Germany), Larissa Knüppel, Yoshihiro Ishikawa, Michaela Aichler, Katharina Heinzelmann, Rudolf Hatz, Jürgen Behr, Axel Walch, Hans Peter Bächinger, Oliver Eickelberg, Claudia A. Staab-Weijnitz. Nintedanib and pirfenidone inhibit collagen synthesis and maturation at several regulatory levels. Eur Respir J 2016; 48: Suppl. 60, 3093

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016

Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013

Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

Nintedanib inhibits contractile activity of lung myofibroblasts in a cellular model of scleroderma associated pulmonary fibrosis
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018




NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFβ1-induced fibroblast differentiation into myofibroblasts
Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung
Year: 2009

BIBF1120 inhibits fibroblasts proliferation and production of the extracellular matrix protein fibulin-1
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Inhibition of pulmonary collagen-I, III and fibrotic cytokins in bleomycin induced pulmonary fibrosis by okam J201
Source: Eur Respir J 2005; 26: Suppl. 49, 81s
Year: 2005

Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy
Source: International Congress 2016 – IPF pathogenesis
Year: 2016


PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013


Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Year: 2009

Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016

Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI
Source: Eur Respir J, 52 (3) 1702314; 10.1183/13993003.02314-2017
Year: 2018



Does endostatin inhibit epithelial repair in idiopathic pulmonary fibrosis?
Source: Eur Respir J 2006; 28: Suppl. 50, 337s
Year: 2006

Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014

PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013


Corticosteroids inhibit perivascular recruitment of IL-6 producing cells, maintain BMPR-II pulmonary expression and prevent pulmonary hypertension in monocrotalin-exposed rats
Source: Eur Respir J 2007; 30: Suppl. 51, 347s
Year: 2007

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis
Source: Eur Respir J 2004; 24: 57-65
Year: 2004



Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015